Nebenwirkungen · Pioglitazone Accord
Pioglitazone Accord 15 mg tablets Pioglitazone Accord 30 mg tablets Pioglitazone Accord 45 mg tablets · Abschnitt 4.8 · PDF-Seite 7
HOS-214045 · Präparat HOS-155248
Adverse reactions reported in excess (> 0.5%) of placebo and as more than an isolated case in patients receiving pioglitazone in double-blind studies are listed below as MedDRA preferred term by system organ class and absolute frequency. Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to< 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data). Within each system organ class, adverse reactions are presented in order of decreasing incidence followed by decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-27T02:00:00Z · SHA-256 3d9c32c106b92ea111d2cd14918d84ab542567902b7440d4cfc8889aa3bb0c68 · Passage 912c871ea959c1d2c74e35e0e688c40534d03e5247bba73dcd065be89e4c5413 · Zeichen 37–630 im Abschnitt